{"id":"W4317213523","doi":"10.1093/ndt/gfad009","title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","year":2023,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":237,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Centers for Disease Control and Prevention; National Institutes of Health; National Heart, Lung, and Blood Institute; Vifor Pharma; Astellas Pharma; Novo Nordisk; Eli Lilly and Company; AstraZeneca; CSL Behring; MyoKardia; McMaster University; Gilead Sciences; FibroGen; Alnylam Pharmaceuticals; European Commission; Sanofi; American Society of Nephrology; GlaxoSmithKline; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen","keywords":"Semaglutide; Medicine; Kidney disease; Diabetes mellitus; Type 2 diabetes; Urology; Internal medicine; Endocrinology; Liraglutide","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06645805,0.003424432,0.004681602,0.001097955,0.002266982,0.003122504,0.002603959,0.006756522,0.01067902],"category_scores_gemma":[0.05269852,0.001982364,0.003706793,0.001311702,0.003908546,0.002662223,0.001513492,0.005372912,0.003302224],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001266973,"about_ca_system_score_gemma":0.0056463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006695754,"about_ca_topic_score_gemma":0.001162669,"domain_scores_codex":[0.9355689,0.05367098,0.003215144,0.003145191,0.002714571,0.001685221],"domain_scores_gemma":[0.9826651,0.006577781,0.002838765,0.002553918,0.002394014,0.002970473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9165706,0.006414184,0.004569158,0.007047506,0.003222249,0.0003317457,0.0005105858,0.0009870596,0.002751666,0.0083092,0.01598803,0.03329793],"study_design_scores_gemma":[0.9108911,0.03697206,0.003858955,0.001480717,0.002938786,0.0001777379,0.0001004186,0.001565609,0.0009166358,0.005725429,0.03526036,0.0001121229],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.07395779,0.009494186,0.01752205,0.01261945,0.009582371,0.8547667,0.01054807,0.0003887728,0.01112068],"genre_scores_gemma":[0.09196162,0.001131823,0.02101836,0.008145899,0.001584296,0.8721045,0.001721091,0.00005191641,0.002280495],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.06645805,"threshold_uncertainty_score":0.351468,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01992195976321406,"score_gpt":0.2595491731959684,"score_spread":0.2396272134327544,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}